sc13gza
     
 
OMB APPROVAL
 
 
OMB Number: 3235-0145
 
 
Expires: February 28, 2009
 
 
Estimated average burden hours per response...10.4
 
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Cumberland Pharmaceuticals Inc.
 
(Name of Issuer)
Common Stock
 
(Title of Class of Securities)
230770109
 
(CUSIP Number)
December 31, 2010
 
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o   Rule 13d-1(b)
 
o   Rule 13d-1(c)
 
þ   Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 

 


 

                     
CUSIP No.
 
230770109 
 

 

           
1   NAMES OF REPORTING PERSONS.

I.R.S. Identification Nos. of above persons (entities only).
A.J. Kazimi
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) Not applicable

  (a)   o
  (b)   o
     
3   SEC USE ONLY
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States
       
  5   SOLE VOTING POWER
     
NUMBER OF   5,517,775
       
SHARES 6   SHARED VOTING POWER
BENEFICIALLY    
BY OWNED BY   None
       
EACH 7   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   5,517,775
       
WITH: 8   SHARED DISPOSITIVE POWER
     
    None
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  5,517,775
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

Not applicable
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  27.1%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN

Page 2 of 5 pages


 

Item 1.
  (a)   Name of Issuer

Cumberland Pharmaceuticals Inc.
 
  (b)   Address of Issuer’s Principal Executive Offices

2525 West End Avenue, Suite 950, Nashville, TN 37203
Item 2.
  (a)   Name of Person Filing

A.J. Kazimi
 
  (b)   Address of Principal Business Office or, if none, Residence

2525 West End Avenue, Suite 950, Nashville, TN 37203
 
  (c)   Citizenship

United States
 
  (d)   Title of Class of Securities

Common Stock
 
  (e)   CUSIP Number

230770109
Item 3.   If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Page 3 of 5 pages


 

Item 4. Ownership.
  (a)   Amount beneficially owned:

5,517,775.
 
  (b)   Percent of class:

27.1%.
 
  (c)   Number of shares as to which the person has:
  (i)   Sole power to vote or to direct the vote

5,517,775.
 
  (ii)   Shared power to vote or to direct the vote

None.
 
  (iii)   Sole power to dispose or to direct the disposition of

5,517,775.
 
  (iv)   Shared power to dispose or to direct the disposition of

None.
Item 5. Ownership of Five Percent or Less of a Class

Not applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding              Company

Not applicable
Item 8. Identification and Classification of Members of the Group

Not applicable
Item 9. Notice of Dissolution of Group

Not applicable
Item 10. Certification

Not applicable

Page 4 of 5 pages


 

SIGNATURE
     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
 
  February 14, 2011
 
   
 
  Date
 
 
  /s/ A.J. Kazimi
 
   
 
  Signature
 
 
  A.J. Kazimi
 
   
 
  Name/Title

Page 5 of 5 pages